Floatz logo

Denosumab

Breast Carcinoma Metastatic in the Bone

Northwestern Universitymonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Breast Carcinoma Metastatic in the Bone cohort.

Asset / SponsorPhaseRating
Ibandronate
Kelly Fitzgerald, MD
Phase 4BBB
Denosumab
Kelly Fitzgerald, MD
Phase 4BBB
Zoledronate
Kelly Fitzgerald, MD
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 3BB
Zometa
Sun Yat-sen University
Phase 4BB

View all 50 →

Same molecule, other indications

Denosumab is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →